Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.272 SEK | -8.49% | -4.65% | -26.69% |
05-08 | Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-14 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.69% | 9.07M | - | - | |
+8.63% | 114B | B+ | ||
+13.17% | 107B | B+ | ||
-12.76% | 22.22B | B+ | ||
-2.39% | 21.28B | B | ||
-5.01% | 18.8B | A- | ||
-7.19% | 17.51B | B | ||
-39.93% | 17.17B | A- | ||
+6.67% | 14.14B | C+ | ||
+33.90% | 12.2B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SPRINT Stock
- Ratings Sprint Bioscience AB